'Pathway drug cocktail': Targeting Ras signaling based on structural pathways

Trends in Molecular Medicine

Volumn 19, Issue 11, 2013, Pages 695-704

  Nussinov, Ruth ^a,b   Tsai, Chung Jung ^a   Mattos, Carla ^c  

^a SAIC FREDERICK INC   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cancer; Classification; Drug discovery; Oncogenic mutations; Parallel pathways; Structures

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAS PROTEIN; SCAFFOLD PROTEIN; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; COLON CANCER; DIMERIZATION; DRUG COMBINATION; DRUG MECHANISM; HUMAN; INTRACELLULAR SIGNALING; MELANOMA; MOLECULAR INTERACTION; NEGATIVE FEEDBACK; PALMITOYLATION; PATHWAY DRUG COCKTAIL; PHARMACODYNAMICS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PRENYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; RECTUM CANCER; REVIEW; SOMATIC MUTATION;

CANCER; CLASSIFICATION; DRUG DISCOVERY; ONCOGENIC MUTATIONS; PARALLEL PATHWAYS; STRUCTURES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84886948259     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.07.009     Document Type: Review

References (71)

1. Fernandez-Medarde A., Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011, 2:344-358.
2. Gysin S., et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
3. Nussinov R., et al. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim. Biophys. Acta 2013, 1834:820-829.
4. Acuner Ozbabacan S.E., et al. Enriching the human apoptosis pathway by predicting the structures of protein-protein complexes. J. Struct. Biol. 2012, 179:338-346.
5. Kiel C., et al. Structural and functional protein network analyses predict novel signaling functions for rhodopsin. Mol. Syst. Biol. 2011, 7:551.
6. Boriack-Sjodin P.A., et al. The structural basis of the activation of Ras by Sos. Nature 1998, 394:337-343.
7. Scheffzek K., et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277:333-338.
8. Wittinghofer A., Vetter I.R. Structure-function relationships of the G domain, a canonical switch motif. Annu. Rev. Biochem. 2011, 80:943-971.
9. Bos J.L., et al. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877.
10. Milburn M.V., et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990, 247:939-945.
11. Buhrman G., et al. Analysis of binding site hot spots on the surface of Ras GTPase. J. Mol. Biol. 2011, 413:773-789.
12. Gorfe A.A., et al. Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure 2008, 16:885-896.
13. Buhrman G., et al. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4931-4936.
14. Gorfe A.A., et al. Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J. Med. Chem. 2007, 50:674-684.
15. Ito Y., et al. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein. Biochemistry 1997, 36:9109-9119.
16. O'Connor C., Kovrigin E.L. Global conformational dynamics in ras. Biochemistry 2008, 47:10244-10246.
17. John J., et al. C-terminal truncation of p21H preserves crucial kinetic and structural properties. J. Biol. Chem. 1989, 264:13086-13092.
18. Buhrman G., et al. Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase. J. Biol. Chem. 2011, 286:3323-3331.
19. Buhrman G., et al. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 2007, 15:1618-1629.
20. Minato T., et al. Quantitative analysis of mutually competitive binding of human Raf-1 and yeast adenylyl cyclase to Ras proteins. J. Biol. Chem. 1994, 269:20845-20851.
21. Martin G.A., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849.
22. Spoerner M., et al. Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J. Biol. Chem. 2010, 285:39768-39778.
23. Prior I.A., et al. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72:2457-2467.
24. Forbes S.A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-D950.
25. Herrmann C., et al. Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J. Biol. Chem. 1996, 271:6794-6800.
26. Pacold M.E., et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103:931-943.
27. Baines A.T., et al. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 2011, 3:1787-1808.
28. Hancock J.F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 2003, 4:373-384.
29. Li Z., Gorfe A.A. What drives the clustering of membrane-bound Ras?. Small GTPases 2012, 3:244-247.
30. Konstantinopoulos P.A., et al. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6:541-555.
31. Sos M.L., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18351-18356.
32. Wang W., et al. Ras inhibition via direct Ras binding - is there a path forward?. Bioorg. Med. Chem. Lett. 2012, 22:5766-5776.
33. Holzapfel G., et al. Shift in the equilibrium between on and off states of the allosteric switch in Ras-GppNHp affected by small molecules and bulk solvent composition. Biochemistry 2012, 51:6114-6126.
34. Liu J., Nussinov R. The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: conformational control of substrate orientation. PLoS Comput. Biol. 2009, 5:e1000527.
35. Brennan D.F., et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011, 472:366-369.
36. Lackner M.R., et al. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 2012, 8:999-1014.
37. Corcoran R.B., et al. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011, 2:336-346.
38. Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
39. Nazarian R., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
40. Wagle N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 2011, 29:3085-3096.
41. Little A.S., et al. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A.S. Little, K. Balmanno, M.J. Sale, S. Newman, J.R. Dry, M. Hampson, P.A.W. Edwards, P.D. Smith, S.J. Cook. Sci. Signal. 2011, 4:er2.
42. Little A.S., et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 2011, 4:ra17.
43. DeVita V.T., Schein P.S. The use of drugs in combination for the treatment of cancer: rationale and results. N. Engl. J. Med. 1973, 288:998-1006.
44. Held M.A., et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov. 2013, 3:52-67.
45. Corcoran R.B., et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 2010, 3:ra84.
46. Lee M.J., et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.
47. Kuzu G., et al. Constructing structural networks of signaling pathways on the proteome scale. Curr. Opin. Struct. Biol. 2012, 22:367-377.
48. Tuncbag N., et al. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat. Protoc. 2011, 6:1341-1354.
49. Lito P., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
50. Hatzivassiliou G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
51. Heidorn S.J., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
52. Villanueva J., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
53. Bradshaw J.M. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell. Signal. 2010, 22:1175-1184.
54. Jia J., et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8:111-128.
55. Boehr D.D., et al. The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 2009, 5:789-796.
56. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 2001, 93:1062-1074.
57. Hantschel O., et al. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012, 72:4890-4895.
58. Hirai H., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1956-1967.
59. Corcoran R.B., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
60. Arozarena I., et al. Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. Genes Cancer 2011, 2:182-194.
61. Rajalingam K., et al. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 2007, 1773:1177-1195.
62. Stites E.C., Ravichandran K.S. A systems perspective of ras signaling in cancer. Clin. Cancer Res. 2009, 15:1510-1513.
63. Cox A.D., Der C.J. Ras history: the saga continues. Small GTPases 2010, 1:2-27.
64. Ahearn I.M., et al. Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 2012, 13:39-51.
65. Kanehisa M. Molecular network analysis of diseases and drugs in KEGG. Methods Mol. Biol. 2013, 939:263-275.
66. Kouranov A., et al. The RCSB PDB information portal for structural genomics. Nucleic Acids Res. 2006, 34:D302-D305.
67. Straub C.S. Targeting IAPs as an approach to anti-cancer therapy. Curr. Top. Med. Chem. 2011, 11:291-316.
68. Chang E.H., et al. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:4848-4852.
69. Pylayeva-Gupta Y., et al. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
70. Naguib A., et al. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J. Mol. Signal. 2011, 6:2.
71. Janakiraman M., et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010, 70:5901-5911.